{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:10Z","timestamp":1777934650925,"version":"3.51.4"},"reference-count":62,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bisphosphonates (P-C-Ps) also called diphosphonates are the structural analogs of naturally occurring pyrophosphates. Bisphosphonates are traditionally used and shown to provide long-term success in the treatment and prevention of osteoporosis and other bone loss pathologies. Furthermore, bisphosphonates are gaining popularity in the present era of cancer therapeutics and prevention. The usage of bisphosphonates as adjuvant or neoadjuvant therapy, either as a single agent or combined with other chemotherapy, has been studied in different solid tumors. This review aims to present the various roles of bisphosphonates in solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Articles in MEDLINE\/PubMed and the National Institutes of Health Clinical Trials Registry ( http:\/\/www . Clinicaltrials.gov) between 1 January 2011 and 1 February 2022 were extracted using MeSH terms \u201cbisphosphonates\/diphosphosphonates and mechanism,\u201d \u201cbisphosphonates and breast cancer,\u201d \u201cbisphosphonates and prostate cancer,\u201d \u201cbisphosphonates and lung cancer,\u201d \u201cbisphosphonates and cancer risk,\u201d and \u201cbisphosphonates and adverse events.\u201d Manual searches of some major oncology journals were also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This review article focuses on the antitumor activity of bisphosphonates, safety profile, and the role of bisphosphonates as preventive, neoadjuvant, and adjuvant chemotherapy. A significant improvement in overall survival and cancer-specific survival and recurrence-free survival with the usage of bisphosphonates is noted in breast cancer patients, particularly in post-menopausal women. Though great progress has been achieved in over 20 years, further research is needed to identify the subgroup of patients that are most likely to benefit from adjuvant bisphosphonate therapy and to determine regimens with greater efficacy and better safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241265304","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T05:26:24Z","timestamp":1721971584000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-629X","authenticated-orcid":false,"given":"Sindhusha","family":"Veeraballi","sequence":"first","affiliation":[{"name":"Saint Michael's Medical Center, Internal Medicine Residency, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Samyuktha","family":"Bandaru","sequence":"additional","affiliation":[{"name":"Baton Rouge General Internal Medicine Residency Program, Baton Rouge, LA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystina","family":"Kiwan","sequence":"additional","affiliation":[{"name":"Saint Michael's Medical Center, Internal Medicine Residency, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-1122","authenticated-orcid":false,"given":"Kok Hoe","family":"Chan","sequence":"additional","affiliation":[{"name":"McGovern Medical School, University of Texas Health Science Center at Houston, Houston, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9901-5883","authenticated-orcid":false,"given":"Hamid S","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Saint Michael's Medical Center, Hematology Oncology, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"bibr1-10781552241265304","doi-asserted-by":"crossref","unstructured":"Diab DL, Watts NB, Miller PD.\n                      Bisphosphonates: pharmacology and use in the treatment of osteoporosis. Marcus and Feldman's osteoporosis\n                      . Elsevier; 2021. pp. 1721\u20131736.","DOI":"10.1016\/B978-0-12-813073-5.00074-5"},{"key":"bibr2-10781552241265304","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032"},{"key":"bibr3-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4302"},{"key":"bibr4-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115907"},{"key":"bibr5-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"bibr6-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3922-0"},{"key":"bibr7-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.003"},{"key":"bibr8-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.11.008"},{"key":"bibr9-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0520"},{"key":"bibr10-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154264"},{"key":"bibr11-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.10.005"},{"key":"bibr12-10781552241265304","doi-asserted-by":"crossref","unstructured":"Balean OI, Atena G, Jumanca D, et al. In vitro Effect of Bisphosphonates on Squamous Cell Carcinoma from Tongue Tissue.\n                      Rev Chim\n                      2019.","DOI":"10.37358\/RC.19.2.6980"},{"key":"bibr13-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115493"},{"key":"bibr14-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421422111"},{"key":"bibr15-10781552241265304","doi-asserted-by":"crossref","unstructured":"Munoz MA, Rogers MJ. Cellular and molecular actions of bisphosphonates. 2022.","DOI":"10.1016\/B978-0-12-821666-8.00025-6"},{"key":"bibr16-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105111"},{"key":"bibr17-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0623-8"},{"key":"bibr18-10781552241265304","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1226"},{"key":"bibr19-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1861246"},{"key":"bibr20-10781552241265304","doi-asserted-by":"publisher","DOI":"10.2165\/11585470-000000000-00000"},{"key":"bibr21-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.06.007"},{"key":"bibr22-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.014"},{"key":"bibr23-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05748-8"},{"key":"bibr24-10781552241265304","doi-asserted-by":"crossref","unstructured":"Byrne H, Weadick CS, Ni Riordain R, et al. 2059P The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre. DOI: https:\/\/doi.org\/10.1016\/j.annonc.2023.09.841","DOI":"10.1016\/j.annonc.2023.09.841"},{"key":"bibr25-10781552241265304","doi-asserted-by":"crossref","unstructured":"M\u00fccke T, Deppe H, Hein J, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid\u2014a prospective study over 6 years. PMID: 27555374. DOI: https:\/\/doi.org\/10.1016\/j.jcms.2016.07.026","DOI":"10.1016\/j.jcms.2016.07.026"},{"key":"bibr26-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01186"},{"key":"bibr27-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90232-5"},{"key":"bibr28-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605555"},{"key":"bibr29-10781552241265304","first-page":"1","volume":"14","year":"2018","journal-title":"Arch Osteoporos"},{"key":"bibr30-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01043-9"},{"key":"bibr31-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.9530"},{"key":"bibr32-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5606573"},{"key":"bibr33-10781552241265304","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00495"},{"key":"bibr34-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06100-2"},{"key":"bibr35-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1180-6"},{"key":"bibr36-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2017.05.066"},{"key":"bibr37-10781552241265304","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.\n                      N Engl J Med\n                      2009.","DOI":"10.2147\/OTT.S4082"},{"key":"bibr38-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"bibr39-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7257"},{"key":"bibr40-10781552241265304","doi-asserted-by":"crossref","unstructured":"O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10: Cd003474.","DOI":"10.1002\/14651858.CD003474.pub4"},{"key":"bibr41-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1159\/000499931"},{"key":"bibr42-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06147-1"},{"key":"bibr43-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100339"},{"key":"bibr44-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz215"},{"key":"bibr45-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1854"},{"key":"bibr46-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02647"},{"key":"bibr47-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30603-4"},{"key":"bibr48-10781552241265304","doi-asserted-by":"crossref","unstructured":"Paterson AHG, Lucas PC, Anderson SJ, et al. MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential impact on clinical practice. JNCI Cancer Spectr 2021; 5.","DOI":"10.1093\/jncics\/pkab054"},{"key":"bibr49-10781552241265304","unstructured":"gov,C.thttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04045522?cond=NCT04045522&draw=2&rank=1"},{"key":"bibr50-10781552241265304","unstructured":"gov,N.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03358017?cond=NCT03358017&draw=2&rank=1"},{"key":"bibr51-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.04.014"},{"key":"bibr52-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"bibr53-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"bibr54-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"bibr55-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu519"},{"key":"bibr56-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146"},{"key":"bibr57-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.04.023"},{"key":"bibr58-10781552241265304","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-6-200703200-00006"},{"key":"bibr59-10781552241265304","unstructured":"ClinicalTrials.gov identifier: NCT01344330, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01344330."},{"key":"bibr60-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds128"},{"key":"bibr61-10781552241265304","unstructured":"ClinicalTrials.gov identifier: NCT00765687. Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates (BLEST). ClinicalTrials.gov. Last updated: [12\/10\/2013], https:\/\/classic.clinicaltrials.gov\/show\/NCT00765687 (accessed 03\/10\/2022)."},{"key":"bibr62-10781552241265304","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt225"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241265304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241265304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241265304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:03Z","timestamp":1777689003000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241265304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/10781552241265304"],"URL":"https:\/\/doi.org\/10.1177\/10781552241265304","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}